fcmedicineФундаментальная и клиническая медицинаFundamental and Clinical Medicine2500-07642542-0941КемГМУ10.23946/2500-0764-2019-4-2-84-94fcmedicine-147Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESМатриксные металлопротеиназы. Клиническая и прогностическая значимость у больных инфарктом миокардаClinical and prognostic significance of matrix metalloproteinases in patients with myocardial infarctionhttps://orcid.org/0000-0002-4771-484XПечеринаТ. Б.PecherinaT. B.

Печерина Тамара Борзалиевна - кандидат медицинских наук, старший научный сотрудниклаборатории патофизиологии мультифокального атеросклероза отдела мультифокального атеросклероза.

650002, Кемерово, б-р Сосновый, д. 6

Dr. Tamara В. Pecherina - MD, PhD, Senior Researcher, Laboratory for Atherosclerosis Pathophysiology, Division of Atherosclerosis Research.

tb.pechorina@gmail.comhttps://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

Барбараш Ольга Леонидовна - доктор медицинских наук, профессор, член-корреспондент РАН, директор ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; заведующая кафедрой кардиологии и сердечно-сосудистой хирургии

Prof. Olga L. Barbarash - MD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Chief Executive Officer.

6, Sosnovy Boulevard, Kemerovo, 650002; 22a, Voroshilova Street, Kemerovo, 650056

 

ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues ofCardiovascular DiseasesRussian FederationФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ФГБОУ ВО «Кемеровский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияResearch Institute for Complex Issues ofCardiovascular Diseases; Kemerovo State Medical UniversityRussian Federation201930062019428494Copyright © Печерина Т.Б., Барбараш О.Л., 20192019Печерина Т.Б., Барбараш О.Л.Pecherina T.B., Barbarash O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://fcm.kemsmu.ru/jour/article/view/147

Биологические маркеры часто используются в качестве суррогатных точек оценки риска, тяжести и прогноза заболевания. При этом не все из них формально являются потенциально мониторируемыми. Для наиболее оптимального использования биомаркеров в прогнозировании сердечно-сосудистого риска они должны отличаться не только точностью и воспроизводимостью при последовательных количественных измерениях, но и демонстрировать высокую чувствительность и специфичность. В последние годы наряду с классическими биомаркерами некроза миокарда, занявшими прочные позиции в клинике, появились новые - отражающие различные стороны развития патологического процесса при развитии инфаркта миокарда (ИМ): маркеры некроза (тро-понины), активации воспалительного процесса [(С-реактивный белок (СРБ), цитокины, матрикс-ные металлопротеиназы (ММП)] и маркеры миокардиальной дисфункции (предсердный и мозговой натрийуретические пептиды). При этом классические биомаркеры широко используются для своевременной диагностики ИМ, в то время как все большее число новых маркеров рассматриваются с позиции стратификации риска неблагоприятных исходов у больных острым коронарным синдромом (ОКС).

Biomarkers are often used as a surrogate measure in the assessment of risk, severity, and prognosis of the disease. For the optimal use of biomarkers in predicting cardiovascular risk, they should demonstrate reproducibility in sequential quantitative measurements and show high sensitivity and specificity. In recent years, classic biomarkers of myocardial necrosis such as troponins were complemented by inflammatory markers (C-reactive protein, cytokines, matrix metalloproteinases) and markers of myocardial dysfunction (atrial and cerebral natriuretic peptides). Currently, conventional biomarkers are widely used for the timely diagnosis of myocardial infarction while an increasing number of novel markers are utilized to evaluate the risk of adverse outcomes in patients with acute coronary syndrome.

биологические маркерыинфаркт миокардаматриксные металлопротеиназыbiomarkersmyocardial infarctionmatrix metalloproteinasesРабота выполнена при поддержке комплексной программы фундаментальных научных исследований СО РАН в рамках фундаментальной темы НИИ КПССЗ № 0546-2015-0012 «Мультифокальный атеросклероз и комор-бидные состояния. Особенности диагностики, управления рисками в условиях крупного промышленного региона Сибири»The study was performed within the Complex Program of Basic Research of the Siberian Branch of the Russian Academy of Sciences within the Basic Research Topic of Research Institute for Complex Issues of Cardiovascular Diseases # 0546-2015-0012 «Atherosclerosis and its comorbidities. Features of diagnostics and risk management in large industrial region of Siberia»ReferencesГайковая Л.Б., Кухарчик Г.А., Нестерова H.H., Вавилова T.B., Бурбелло A.T., Шабров А.В. Современные лабораторные маркеры в определении прогноза при остром коронарном синдроме и мониторинге терапии II Вестник аритмологии. 2009. № 58. С. 52-59.Gaykovaya LB, Kukharchik GA, Nesterova NN, Vavilova TV, Burbello A, Shabrov AV. Up to date laboratory markers in assessment of the acute coronary synrome prognosis and monitoring of therapy. Bulletin of Arrhythmology. 2009; 58: 52-59. RussianPrentice RL. Surrogate endpoints in clinical trials: definition and operational criteria II Stat Med. 1989; 8 (4): 431-440.Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria II Stat Med. 1989; 8 (4): 431-440.Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113 (19): 23352362. doi: 10.1161/CIRCULATIONAHA.104.482570.Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113 (19): 23352362. doi: 10.1161/CIRCULATIONAHA.104.482570.De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001; 22 (5): 485-502. doi: 10.1016/S0197-2456(01)00153-2.De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001; 22 (5): 485-502. doi: 10.1016/S0197-2456(01)00153-2.Hui BQ, Dang XF, Wang XF, Jin Z, Xia DS, Gao L, et al. Intravascular ultrasound study of coronary remodeling and determination of matrix metalloproteinase and hypersensitive C-reactive protein. Zhongua Xin Xue Guan Bin Za Zhi. 2005; 33 (5): 428-432.Hui BQ, Dang XF, Wang XF, Jin Z, Xia DS, Gao L, et al. Intravascular ultrasound study of coronary remodeling and determination of matrix metalloproteinase and hypersensitive C-reactive protein. Zhongua Xin Xue Guan Bin Za Zhi. 2005; 33 (5): 428-432.Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? II Журнал Сердечная недостаточность. 2000. Т. 1, № 4. С. 135-138.Belenkov YuN, Ageev FT, Mareev VYu. Neurohormones and cytokines in heart failure: a new theory of the old disease? Heart Failure Journal. 2000; 1 (4): 135-138. RussianКапелью В.И. Ремоделирование миокарда: роль матриксных металлопротеиназ II Кардиология. 2001. Т. 41, № 6. С. 49-55.Kapelko VI. Myocardial remodeling: the role of matrix metallo-proteinases. Cardiology. 2001; 41 (6): 49-55. RussianБокарев И.Н., Аксенова М.Б., Хлевчук Т.В. Острый коронарный синдром и его лечение : учеб, пособие для вузов. 2-е изд., испр. и перераб. Москва: Практическая медицина, 2009.172 с.Bokarev IN, Aksyonova MB, Khlevchuk TV. Acute coronary syndrome and its treatment: a textbook. 2nd edition. Moscow: Applied Medicine Publishing House, 2009. 172 p. RussianТурна A.A., Тогузов PT. Матриксные металлопротеиназы и сердечно-сосудистые заболевания II Артериальная гипертензия. 2009. Т. 15, № 5. С. 532-538.Tourna АА, Toguzov RT. Matrix metalloproteinases and cardiovascular diseases. Arterial Hypertension. 2009; 15 (5): 532-538. RussianТуманян C.B., Симочкина О.Ю., Мемарнишвили O.B. Опыт использования шкал APACHE III и SAPS II в качестве критериев тяжести состояния и прогноза у больных с истинным кардиогенным шоком при остром инфаркте миокарда II Вестник интенсивной терапии. 2008. № 1. С. 12-14.Tumanyan SV, Simochkina OYu, Memarnishvili OV. The experience of using the APACHE III and SAPS II scales as criteria for the severity of the condition and prognosis in patients with true cardiogenic shock in acute myocardial infarction. Bulletin of Intensive Care. 2008; 1:12-14. RussianKelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007; 28 (6): 711-718. doi: 10.1093/eu-rheartj/ehm003.Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007; 28 (6): 711-718. doi: 10.1093/eu-rheartj/ehm003.Баркаган 3.C., Костюченко Г.И. Метаболически-воспалительная концепция атеротромбоза и новые подходы к терапии больных II Бюллетень СО РАМН. 2006. Т. 26, № 2. С. 132-138.Barkagan ZS, Kostyuchenko GI. Inflammatory metabolic conception of atherothrombosis and new approaches to therapy of patients. Bulletin of Siberian Branch of Russian Academy of Medical Sciences. 2006; 26 (2): 132-138. RussianMartinez Rosas М. Cardiac remodeling and inflammation. Arch Cardiol Mex. 2006; 76 (suppl. 4): 58-66.Martinez Rosas М. Cardiac remodeling and inflammation. Arch Cardiol Mex. 2006; 76 (suppl. 4): 58-66.Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; 87 (4): 1285-1342. doi: 10.1007/s00251-018-1093-z.Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; 87 (4): 1285-1342. doi: 10.1007/s00251-018-1093-z.Phatharajaree W, Phrommintikul A, Chattipakom N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007; 23 (9): 727-733. doi: 10.1016/S0828-282X(07)70818-8.Phatharajaree W, Phrommintikul A, Chattipakom N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007; 23 (9): 727-733. doi: 10.1016/S0828-282X(07)70818-8.ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. A report of the American College of Cardiology / American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8 (9): 746837. doi: 10.1093/europace/eull08.ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. A report of the American College of Cardiology / American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8 (9): 746837. doi: 10.1093/europace/eull08.Manginas A, Bei E, Chaidaroglou A, Degiannis D, Koniavitou K, Voudris V, et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol. 2005; 28 (4): 182-186. doi: 10.1002/clc.4960280405.Manginas A, Bei E, Chaidaroglou A, Degiannis D, Koniavitou K, Voudris V, et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol. 2005; 28 (4): 182-186. doi: 10.1002/clc.4960280405.Uechima K, Shibata M, Suzuki T, Endo S, Hiramori K. Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase-1, and effects of magnesium pretreatment on reperfusion injury. Magnesium Res. 2003; 16 (2): 120-126.Uechima K, Shibata M, Suzuki T, Endo S, Hiramori K. Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase-1, and effects of magnesium pretreatment on reperfusion injury. Magnesium Res. 2003; 16 (2): 120-126.Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995; 96 (5): 2304-2310. doi: 10.1172/JCI118286.Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995; 96 (5): 2304-2310. doi: 10.1172/JCI118286.Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, et al. TNF-a and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002; 282 (4): 1288-1295. doi: 10.1152/ajpheart.00526.2001.Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, et al. TNF-a and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002; 282 (4): 1288-1295. doi: 10.1152/ajpheart.00526.2001.Aggarwal BB, Natarajan K. Tumor necrosis factors: develompets during the last decade. Europ Cytokine New. 1996. 7 (2): 93-124.Aggarwal BB, Natarajan K. Tumor necrosis factors: develompets during the last decade. Europ Cytokine New. 1996. 7 (2): 93-124.Nilsson L, Eriksson P, Cherfan P, Jonasson L. Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. Inflammation. 2011; 34 (4): 225-230. doi: 10.1007/sl0753-010-9227-y.Nilsson L, Eriksson P, Cherfan P, Jonasson L. Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. Inflammation. 2011; 34 (4): 225-230. doi: 10.1007/sl0753-010-9227-y.Турна A.A., Тогузов P.T. Матриксные металлопротеиназы и сердечно-сосудистые заболевания II Артериальная гипертензия. 2009. Т. 15, № 5. С. 532-538.Turna AA, Toguzov RT. Matrix metalloproteinases and cardiovascular diseases. Arterial Hypertension. 2009; 15 (5): 532-538. RussianGarvin Р, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One. 2008; 3 (3): el774. doi: 10.1371/joumal.pone.0001774.Garvin Р, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One. 2008; 3 (3): el774. doi: 10.1371/joumal.pone.0001774.Nurkic J, Ljuca F, Nurkic M, Jahic E, Jahic M. Biomarkers of plaque instability in acute coronary syndrome patients. Med. Arh. 2010; 64 (2): 103-106.Nurkic J, Ljuca F, Nurkic M, Jahic E, Jahic M. Biomarkers of plaque instability in acute coronary syndrome patients. Med. Arh. 2010; 64 (2): 103-106.Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003; 145 (6): 1094-1101. doi: 10.1016/S0002-8703(03)00098-X.Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003; 145 (6): 1094-1101. doi: 10.1016/S0002-8703(03)00098-X.Gonzalvez M, Ruiz Ros JA, Perez-Paredes M, Lozano ML, Gimenez DM, Martinez-Corbalan F, et al. Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation. Rev Esp Cardiol. 2004; 57 (10): 916-923.Gonzalvez M, Ruiz Ros JA, Perez-Paredes M, Lozano ML, Gimenez DM, Martinez-Corbalan F, et al. Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation. Rev Esp Cardiol. 2004; 57 (10): 916-923.Nakamura T, Ebihara I, Shimada N, Koide H. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin Chim Acta. 1998; 276 (2): 173-177. doi: 10.1016/S0009-8981(98)00104-1.Nakamura T, Ebihara I, Shimada N, Koide H. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin Chim Acta. 1998; 276 (2): 173-177. doi: 10.1016/S0009-8981(98)00104-1.Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364 (9438): 953-962. doi: 10.1016/S0140-6736(04)17019-0.Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364 (9438): 953-962. doi: 10.1016/S0140-6736(04)17019-0.Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol. 2005; 162 (1-2): 1-2. doi: 10.1016/j.jneuroim.2004.12.021.Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol. 2005; 162 (1-2): 1-2. doi: 10.1016/j.jneuroim.2004.12.021.Thrailkill K, Cockrell G, Simpson P, Moreau C, Fowlkes J, Bunn RC. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med. 2006; 44 (4): 503-504. doi: 10.1515/CCLM.2006.090.Thrailkill K, Cockrell G, Simpson P, Moreau C, Fowlkes J, Bunn RC. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med. 2006; 44 (4): 503-504. doi: 10.1515/CCLM.2006.090.Koh KK, Ahn JY, Kang MH, Kim DS, Jin DK, Sohn MS, et al. Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. Am J Cardiol. 2001; 88 (12): 1423-1426. doi.org/10.1016/S0002-9149(01)02126-9.Koh KK, Ahn JY, Kang MH, Kim DS, Jin DK, Sohn MS, et al. Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. Am J Cardiol. 2001; 88 (12): 1423-1426. doi.org/10.1016/S0002-9149(01)02126-9.Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E. Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemostasis. 1994; 72 (2): 302-308.Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E. Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemostasis. 1994; 72 (2): 302-308.Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54 (23): 2129-2138. doi: 10.1016/j.jacc.2009.09.009.Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54 (23): 2129-2138. doi: 10.1016/j.jacc.2009.09.009.Pollanen JP, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttila A, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene. Arterioscler Thromb Vase Biol. 2001; 21(9): 1446-1450.Pollanen JP, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttila A, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene. Arterioscler Thromb Vase Biol. 2001; 21(9): 1446-1450.Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vase Med. 2005; 10 (1): 1-6. doi: 10.1191/1358863x05vm582oa.Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vase Med. 2005; 10 (1): 1-6. doi: 10.1191/1358863x05vm582oa.Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vase Biol. 2003; 23 (2): 283-288.Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vase Biol. 2003; 23 (2): 283-288.Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004; 109 (23): 2850-2856. doi: 10.1161/01.CIR.0000129318.79570.84.Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004; 109 (23): 2850-2856. doi: 10.1161/01.CIR.0000129318.79570.84.Papazafiropoulou A, Perrea D, Moyssakis I, Kokkinos A, Katsil-ambros N, Tentolouris N. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complications. 2010; 24 (1): 20-27. doi: 10.1016/j.jdiacomp.2008.10.004.Papazafiropoulou A, Perrea D, Moyssakis I, Kokkinos A, Katsil-ambros N, Tentolouris N. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complications. 2010; 24 (1): 20-27. doi: 10.1016/j.jdiacomp.2008.10.004.Death AK, Fisher EJ, McGrath КС, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis. 2003; 168 (2): 263-269. doi: 10.1016/S0021-9150(03)00140-0.Death AK, Fisher EJ, McGrath КС, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis. 2003; 168 (2): 263-269. doi: 10.1016/S0021-9150(03)00140-0.Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Failure. 2008; 10 (2): 133-139. doi: 10.1016/j.ejheart.2007.12.009.Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Failure. 2008; 10 (2): 133-139. doi: 10.1016/j.ejheart.2007.12.009.Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease. Open Cardiovasc Med J. 2011; 5: 110-116. doi: 10.2174/1874192401105010110.Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease. Open Cardiovasc Med J. 2011; 5: 110-116. doi: 10.2174/1874192401105010110.Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vase Biol. 1999; 19: 2348-2354.Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vase Biol. 1999; 19: 2348-2354.Wang, J, Xu D, Wu X, Zhou C, Wang H, Guo Y, et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart. 2011; 97 (19): 1542-1546. doi: 10.1136/heartjnl-2011-300342.Wang, J, Xu D, Wu X, Zhou C, Wang H, Guo Y, et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart. 2011; 97 (19): 1542-1546. doi: 10.1136/heartjnl-2011-300342.Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non ST elevation myocardial infarction: the British heart foundation RITA 3 randomised trial. Randomised intervention trial of unstable angina. Lancet. 2002; 360 (9335): 743-751. doi: 10.1016/S0140-6736(02)09894-X.Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non ST elevation myocardial infarction: the British heart foundation RITA 3 randomised trial. Randomised intervention trial of unstable angina. Lancet. 2002; 360 (9335): 743-751. doi: 10.1016/S0140-6736(02)09894-X.Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001; 89 (3): 201-210.Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001; 89 (3): 201-210.James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003; 108 (3): 275281. doi: 10.1161/01.CIR.0000079170.10579.DC.James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003; 108 (3): 275281. doi: 10.1161/01.CIR.0000079170.10579.DC.Xing Z, Zganiacz A, Santosuosso M. Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction. J Leukoc Biol. 2000; 68 (6): 897-902. doi: 10.1189/jlb.68.6.897.Xing Z, Zganiacz A, Santosuosso M. Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction. J Leukoc Biol. 2000; 68 (6): 897-902. doi: 10.1189/jlb.68.6.897.Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis. From pathophysiology to practice. J Am Col Cardiol. 2009; 54 (23): 2129-2138. doi: 10.1016/j.jacc.2009.09.009.Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis. From pathophysiology to practice. J Am Col Cardiol. 2009; 54 (23): 2129-2138. doi: 10.1016/j.jacc.2009.09.009.Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, GawA, Gensini G, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Ator-vastatin Stratified Titration. Am Heart J. 2007; 153 (5): 881-888. doi: 10.1016/j.ahj.2007.02.029.Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, GawA, Gensini G, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Ator-vastatin Stratified Titration. Am Heart J. 2007; 153 (5): 881-888. doi: 10.1016/j.ahj.2007.02.029.Alan S. Maisel Cardiac Biomarkers: Expert Advice for Clinicians. JP: Medical Ltd, 2012. 239 p.Alan S. Maisel Cardiac Biomarkers: Expert Advice for Clinicians. JP: Medical Ltd, 2012. 239 p.Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107 (12): 1579-1585. doi: 10.1161/01.CIR.0000058700.41738.12.Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107 (12): 1579-1585. doi: 10.1161/01.CIR.0000058700.41738.12.Armstrong E, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part IV: Matrix metalloproteinases and biomarkers of platelet activation. Circulation. 2006; 113 (9): 382-385. doi: 10.1161/CIRCULATIONAHA.105.595553.Armstrong E, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part IV: Matrix metalloproteinases and biomarkers of platelet activation. Circulation. 2006; 113 (9): 382-385. doi: 10.1161/CIRCULATIONAHA.105.595553.Nagesh C, Roy A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J Med Res. 2010; 132 (5): 627-633. doi: 10.4103/0971-5916.73419.Nagesh C, Roy A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J Med Res. 2010; 132 (5): 627-633. doi: 10.4103/0971-5916.73419.Spinale FG. Matrix metalloproteinases. Regulation and dysregula-tion in the failing heart. Circ Res. 2002; 90 (5): 520-530.Spinale FG. Matrix metalloproteinases. Regulation and dysregula-tion in the failing heart. Circ Res. 2002; 90 (5): 520-530.Hojo Y, Ikeda U, Katsuki Ta, Mizuno O, Fujikawa H, Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis. 2002; 161 (1): 185-192. doi: 10.1016/S0021-9150(01)00615-3.Hojo Y, Ikeda U, Katsuki Ta, Mizuno O, Fujikawa H, Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis. 2002; 161 (1): 185-192. doi: 10.1016/S0021-9150(01)00615-3.Dorent R, Beaudeux JL, Tezenas S, Ghossoub JJ, Roussouliere AL, Leger P, et al. Circulating Levels of Matrix Metalloproteinas-es in Heart Transplant Recipients. Transplant Proc. 2000; 32 (8): 2750-2751. doi: 10.1016/S0041-1345(00)01866-2.Dorent R, Beaudeux JL, Tezenas S, Ghossoub JJ, Roussouliere AL, Leger P, et al. Circulating Levels of Matrix Metalloproteinas-es in Heart Transplant Recipients. Transplant Proc. 2000; 32 (8): 2750-2751. doi: 10.1016/S0041-1345(00)01866-2.Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation. 2006; 114 (17): 1847-1854. doi: 10.1161/CIRCULATIONA-HA.105.593483.Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation. 2006; 114 (17): 1847-1854. doi: 10.1161/CIRCULATIONA-HA.105.593483.Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol. 2004; 43 (11): 1954-1958. doi: 10.1016/j.jacc.2004.01.045.Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol. 2004; 43 (11): 1954-1958. doi: 10.1016/j.jacc.2004.01.045.Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallon-geville J, Amouyel P, et al. Prognostic impact of matrix metalloproteinase gene polymorphism in patients with heart failure according to the etiology of left ventricular systolic dysfunction. Eur Heart J. 2004; 25 (8): 688-693. doi: 10.1016/j.ehj.2004.01.015.Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallon-geville J, Amouyel P, et al. Prognostic impact of matrix metalloproteinase gene polymorphism in patients with heart failure according to the etiology of left ventricular systolic dysfunction. Eur Heart J. 2004; 25 (8): 688-693. doi: 10.1016/j.ehj.2004.01.015.Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005; 3 (9): 537545. doi: 10.1111/j.l365-2362.2005.01548.x.Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005; 3 (9): 537545. doi: 10.1111/j.l365-2362.2005.01548.x.Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006; 69 (3): 636-645. doi 10.1016/j.cardiores.2005.07.015.Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006; 69 (3): 636-645. doi 10.1016/j.cardiores.2005.07.015.Karapanagiotidis GT, Antonitsis P, Charokopos N, Foroulis CN, Anastasiadis K, Rouska E, et al. Serum levels of matrix metalloproteinases -l,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiothorac Surg. 2009; 4: 59. doi: 10.1186/1749-8090-4-59.Karapanagiotidis GT, Antonitsis P, Charokopos N, Foroulis CN, Anastasiadis K, Rouska E, et al. Serum levels of matrix metalloproteinases -l,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiothorac Surg. 2009; 4: 59. doi: 10.1186/1749-8090-4-59.Dorent R, Beaudeux JL, Tezenas S, Ghossoub JJ, Roussouliere AL, Leger P, et al. Circulating Levels of Matrix Metalloproteinas-es in Heart Transplant Recipients. Transplant Proc. 2000; 32 (8): 2750-2751. doi: 10.1016/S0041-1345(00)01866-2.Dorent R, Beaudeux JL, Tezenas S, Ghossoub JJ, Roussouliere AL, Leger P, et al. Circulating Levels of Matrix Metalloproteinas-es in Heart Transplant Recipients. Transplant Proc. 2000; 32 (8): 2750-2751. doi: 10.1016/S0041-1345(00)01866-2.Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid arherosclero-sis in infraclinical hyperlipidemia. Atherosclerosis. 2003; 169 (1): 139-146. doi: 10.1016/S0021-9150(03)00149-7.Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid arherosclero-sis in infraclinical hyperlipidemia. Atherosclerosis. 2003; 169 (1): 139-146. doi: 10.1016/S0021-9150(03)00149-7.West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J. 2008; 29 (7): 923-931. doi: 10.1093/eurheartj/ehn007.West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J. 2008; 29 (7): 923-931. doi: 10.1093/eurheartj/ehn007.Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, et al. Comparison of Levels of Serum Matrix Metalloproteinase-9 in Patients With Acute Myocardial Infarction Versus Unstable Angina Pectoris Versus Stable Angina Pectoris. Am J Cardiol. 2006; 97 (2): 175-180. doi: 10.1016/j.amj-card.2005.08.020.Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, et al. Comparison of Levels of Serum Matrix Metalloproteinase-9 in Patients With Acute Myocardial Infarction Versus Unstable Angina Pectoris Versus Stable Angina Pectoris. Am J Cardiol. 2006; 97 (2): 175-180. doi: 10.1016/j.amj-card.2005.08.020.Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996; 335(18): 1333-1341. doi: 10.1056/NEJM199610313351801.Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996; 335(18): 1333-1341. doi: 10.1056/NEJM199610313351801.

The authors declare that there are no conflicts of interest present.